Peter Marks, formerly director of the FDA’s Center for Biologics Evaluation and Research (CBER), joined Eli Lilly as senior vice president for molecule discovery and head of infectious disease. Marks leaves a decade of regulatory experience overseeing vaccines, blood products and genetic medicines and was a central figure in Operation Warp Speed and many cell and gene therapy reviews. Lilly framed the hire as strengthening discovery capabilities across multiple therapeutic areas; analysts saw value in Marks’ regulatory and translational knowledge for molecule discovery and infectious disease programs. The move also highlights continued movement of senior regulators into industry roles where regulatory insight can accelerate development and commercial strategies.